SCHEMBL3097645

SCHEMBL3097645

CCN(CC)C(=O)C(Cc1ccc(NC(=O)c2cccc(Cl)c2)cc1)C(=O)NS(=O)(=O)c1ccc2ccccc2c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KAT6A Q92794 1/20 0.49
MAPT P10636 2/20 0.45
TP53 P04637 1/20 0.45
GPR17 Q13304 1/20 0.44
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44
POLB P06746 2/20 0.43
PPARA Q07869 1/20 0.42
BCL2L1 Q07817 1/20 0.42
MCL1 Q07820 1/20 0.42
HSD11B1 P28845 1/20 0.42
KDM4E B2RXH2 2/20 0.42
GAA P10253 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
F2 P00734 1/20 0.42
NPC1 O15118 1/20 0.41
CASP3 P42574 1/20 0.41
RAB9A P51151 1/20 0.41
SENP8 Q96LD8 1/20 0.41
SENP7 Q9BQF6 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3090974 0.92 MEN1 (0.50) KAT6AMAPTMEN1KMT2APPARA
SCHEMBL3093901 0.92 MMP9 (0.46) KAT6AMEN1KMT2APPARAF2
SCHEMBL3102970 0.92 MMP9 (0.46) KAT6AMEN1KMT2APPARAF2
SCHEMBL3092720 0.91 MEN1 (0.53) KAT6AMAPTTP53GPR17MEN1
SCHEMBL3096373 0.90 NPC1 (0.52) KAT6AMAPTMEN1KMT2APOLB
SCHEMBL3088948 0.90 PRMT1 (0.47) MAPTTP53MEN1KMT2ABCL2L1
SCHEMBL3085893 0.90 NPC1 (0.52) KAT6AMAPTMEN1KMT2APOLB
SCHEMBL3093289 0.90 KAT6A (0.49) KAT6AMEN1KMT2APOLBF2
SCHEMBL3080048 0.89 MEN1 (0.54) KAT6AMAPTMEN1KMT2APOLB
SCHEMBL3092605 0.88 KMT2A (0.55) MAPTGPR17MEN1KMT2APOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8461209-B2 Malonic acid sulfonamide derivative and pharmaceutical use thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2013-06-11 US disclosed
US-20100228026-A1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF MITSUBISHI TANABE PHARMA CORPORATION (JP) 2010-09-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100228026-A1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF REN, AGTR2, AGTR1 KAT6A 3337/4885MAPT 2813/4885TP53 3377/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.